Expression of the prostate-specific membrane antigen.

R. Israeli,C. T. Powell,J. Corr,W. Fair,W. Heston

Published 1994 in Cancer Research

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
1994
Venue
Cancer Research
Publication date
1994-04-01
Fields of study
Biology, Medicine
Identifiers
PMID 7511053
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
1993cited by this paper
Prostate cancer. An overview of an increasing dilemma
1993cited by this paper
Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line.
1992cited by this paper
National Cancer Institute roundtable on prostate cancer: future research directions.
1991cited by this paper
36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO.
1991cited by this paper
Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
1990cited by this paper
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
1987cited by this paper
Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.
1984cited by this paper
LNCaP model of human prostatic carcinoma.
1983cited by this paper
A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies.
1981cited by this paper
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
1979cited by this paper
Isolation of a human prostate carcinoma cell line (DU 145)
1978cited by this paper
Ribonucleic acid isolated by cesium chloride centrifugation.
1974cited by this paper
Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.
1972cited by this paper

CITED BY

Unveiling Prostate-Specific Membrane Antigen’s Potential in Breast Cancer Management
2025cites this paper
Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions
2025cites this paper
Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care.
2025cites this paper
Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr.
2025cites this paper
Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers.
2025cites this paper
Chronic Prostate Cancer-Related Symptoms and Toxicities Following Stereotactic Body Radiation Therapy: Implications for Future Radionuclide Therapy
2025cites this paper
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
2025cites this paper
Baseline Imaging Derived Factors of Response Following [225Ac]Ac‐J591 Therapy in Metastatic Castration‐Resistant Prostate Cancer: A Lesion Level Analysis
2025cites this paper
A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software.
2025cites this paper
Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer
2024cites this paper
“One Method to Label Them All”: A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617
2024cites this paper
Physiological 68Ga-PSMA-11 Uptake in Dural Venous Sinuses.
2024cites this paper
New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.
2024cites this paper
Heterogeneous PSMA ligand uptake inside parotid glands.
2024cites this paper
[68Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma
2024cites this paper
Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer
2024cites this paper
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas
2024cites this paper
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024cites this paper
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.
2024cites this paper
PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications
2023cites this paper
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer
2023cites this paper
Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
2023cites this paper
PSMA PET/CT as a predictive tool for subregional importance estimates in the parotid gland
2023cites this paper
Radiotheranostics in advanced prostate cancer: Current and future directions
2023cites this paper
Genetic implications of PSMA expression variability in breast cancer subtypes with a focus on triple-negative breast cancer
2023cites this paper
The past and present of prostate cancer and its treatment and diagnostics: A historical review
2023cites this paper
Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
2023cites this paper
18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
2023cites this paper
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
2023cites this paper
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
2023cites this paper
Novel Multiparametric Magnetic Resonance Imaging-Based Deep Learning and Clinical Parameter Integration for the Prediction of Long-Term Biochemical Recurrence-Free Survival in Prostate Cancer after Radical Prostatectomy
2023cites this paper
Neural blind deconvolution for deblurring and supersampling PSMA PET
2023cites this paper
The clinical signification and application value of [^68Ga]Ga-PSMA imaging in thyroid malignancy
2023cites this paper
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
2023cites this paper
Radiolabeling and in vivo evaluation of lanmodulin with biomedically relevant lanthanide isotopes
2023cites this paper
An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
2022cites this paper
A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer
2022cites this paper
The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.
2022cites this paper
The Value of Phenotypic Precision Medicine in Prostate Cancer
2022cites this paper
Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.
2022cites this paper
Genitourinary tumors
2022cites this paper
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
2022cites this paper
Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study
2022cites this paper
Selective delivery of clinically approved tubulin binding agents through covalent conjugation to an active targeting moiety.
2022cites this paper
Warren D.W. Heston, PhD and Neil H. Bander, MD: Founding Fathers of PSMA Technology.
2022cites this paper
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
2022cites this paper
A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
2022cites this paper
Imaging of Tumor-Associated Vascular Prostate-Specific Membrane Antigen in Woodchuck Model of Hepatocellular Carcinoma
2022cites this paper
Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
2022cites this paper
The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer
2022cites this paper
Nanovaccines with cell-derived components for cancer immunotherapy.
2022cites this paper
Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer
2022cites this paper
Cancers and Benign Processes on 68 Ga PSMA PET-CT Imaging Other than Prostate Cancer
2022cites this paper
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
2022cites this paper
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
2022cites this paper
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
2021cites this paper
Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
2021cites this paper
PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu- PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review
2021cites this paper
ИСПОЛЬЗОВАНИЕ 177 Lu-ПСМА ДЛЯ РАДИОНУКЛИДНОЙ ТЕРАПИИ У ПАЦИЕНТОВ С КАСТРАЦИОННО-РЕЗИСТЕНТНЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
2021cites this paper
PT-BR: Radioterapia PSMA-ligante dirigida com Lutécio 177 como um tratamento para câncer de próstata resistente a castração: uma revisão sistemática
2021cites this paper
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer
2021cites this paper
Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects
2021cites this paper
Locoregional Radionuclide Cancer Therapy: Clinical and Scientific Aspects
2021cites this paper
Comparison of Quantification of Target-Specific Accumulation of [18F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI
2021cites this paper
The effect of eating on the uptake of PSMA ligands in the salivary glands
2021cites this paper
Combining radionuclide therapy with radiotherapy
2021cites this paper
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
2021cites this paper
Prostate Cancer Theranostics: From Target Description to Imaging.
2021cites this paper
A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
2021cites this paper
Competition (‘Steal’ Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue
2021cites this paper
Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers
2021cites this paper
Are heterobivalent GRPR- and VPAC1R-bispecific radiopeptides suitable for efficient in vivo tumor imaging of prostate carcinomas?
2021cites this paper
Multiparametric Magnetic Resonance Imaging, 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography–Computed Tomography, and Respective Quantitative Parameters in Detection and Localization of Clinically Significant Prostate Cancer in Intermediate- and High-Risk Group Patients: An India
2021cites this paper
Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.
2021cites this paper
Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
2021cites this paper
A Structure‐Activity Relationship Study of Bimodal BODIPY‐Labeled PSMA‐Targeting Bioconjugates
2021cites this paper
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
2021cites this paper
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
2021cites this paper
Urologic Cancer Molecular Biology
2021cites this paper
Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
2021cites this paper
Adenoid cystic carcinoma: A review of clinical features, treatment targets and advancement in improving the immune response to monoclonal antibody therapy.
2021cites this paper
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
2021cites this paper
Reduction of radiation accumulation in salivary glands through oral vitamin C during 68Ga-PSMA-11 total-body dynamic PET/CT imaging
2021cites this paper
Validation of HPLC method for the determination of chemical andradiochemical purity of a 68Ga-labelled EuK-Sub-kf-(3-iodo-y-) DOTAGA
2021cites this paper
The Role of Theranostics in Prostate Cancer.
2021cites this paper
Impact of short‐term Dutasteride treatment on prostate‐specific membrane antigen expression in a mouse xenograft model
2021cites this paper
Animal Cancer Therapy Models: Ready Translation to Humans
2020cites this paper
Enyzmes | Glutamate Carboxypeptidase II (EC 3.4.17.21)
2020cites this paper
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
2020cites this paper
Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
2020cites this paper
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
2020cites this paper
Platinum Complexes in Medicine and in the Treatment of Cancer
2020cites this paper
Determination of split renal function by PSMA imaging: comparison of 68Ga-PSMA-11 PET with 99mTc-MAG3 scintigraphy.
2020cites this paper
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
2020cites this paper
Non-FDG PET/CT.
2020cites this paper
Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
2020cites this paper
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
2020cites this paper
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
2020cites this paper
scFv Cloning, Vectors, and CAR-T Production in Laboratory for Preclinical Applications
2020cites this paper
Benefit of including CT urography in 68Ga-PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis.
2020cites this paper